Aveanna Healthcare priced a secondary stock offering of 15 million shares at $11.75 each, expected to settle August 24, 2026.
Quiver AI Summary
Aveanna Healthcare Holdings Inc. has announced the pricing of a secondary offering of 15 million shares of its common stock at $11.75 per share, conducted by certain selling stockholders, including affiliates of J.H. Whitney Equity Partners and current and former company directors. An additional 2.25 million shares may be purchased by the underwriter within 30 days. The proceeds will go entirely to the selling stockholders, as the company itself is not selling shares and will not benefit from the proceeds. The offering is set to close on August 24, 2026, subject to standard conditions. RBC Capital Markets is the sole book-running manager for this offering, which has been registered with the SEC. Further investment information is available through the SEC's EDGAR database or directly from RBC Capital Markets. The release also contains forward-looking statements about the company’s future, which are subject to various risks and uncertainties.
Potential Positives
- The pricing of the secondary offering at $11.75 per share indicates potential strong demand for Aveanna Healthcare's stock, reflecting positive market interest.
- The inclusion of a 30-day option for underwriters to purchase additional shares could signal confidence from investors and may further increase liquidity in the market.
- The effective shelf registration statement allows the company greater flexibility for future fundraising efforts without needing to file new registration statements each time.
- The company's comprehensive range of healthcare services provided across 39 states can enhance its market position and appeal, supporting growth in service demand and revenues.
Potential Negatives
- The secondary offering involves the sale of 15,000,000 shares by selling stockholders, including affiliates of a private equity firm and current/former directors, which may raise concerns about insider selling and the potential impact on stock price.
- The company will not receive any proceeds from the offering, which may indicate financial dependence on external parties rather than sustainable growth.
- The release highlights risks associated with forward-looking statements, signaling uncertainty in the company's future performance and reliance on assumptions that may prove incorrect.
FAQ
What is the secondary offering announced by Aveanna Healthcare?
Aveanna Healthcare is conducting a secondary offering of 15 million shares of common stock at $11.75 per share.
Who will receive the proceeds from the secondary offering?
The Selling Stockholders will receive all net proceeds from the offering; Aveanna Healthcare will not receive any proceeds.
What role does RBC Capital Markets play in this offering?
RBC Capital Markets is acting as the sole book-running manager for the secondary offering.
When is the expected settlement date for the offering?
The offering is expected to settle on August 24, 2026, subject to customary closing conditions.
Where can I find the prospectus for the offering?
The prospectus can be accessed through EDGAR on the SEC website or by contacting RBC Capital Markets directly.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVAH Insider Trading Activity
$AVAH insiders have traded $AVAH stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $AVAH stock by insiders over the last 6 months:
- PAUL R VIGANO has made 0 purchases and 9 sales selling 11,000,000 shares for an estimated $75,710,000.
- ROBERT M JR WILLIAMS has made 0 purchases and 9 sales selling 11,000,000 shares for an estimated $75,710,000.
- WHITNEY EQUITY PARTNERS VII, LLC J.H. has made 0 purchases and 3 sales selling 9,180,664 shares for an estimated $63,187,159.
- PATRICK A. CUNNINGHAM (Chief Compliance Officer) sold 125,000 shares for an estimated $948,537
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AVAH Revenue
$AVAH had revenues of $670.5M in Q2 2026. This is an increase of 13.73% from the same period in the prior year.
You can track AVAH financials on Quiver Quantitative's AVAH stock page.
You can access data on AVAH stock through the Quiver Quantitative API.
$AVAH Hedge Fund Activity
We have seen 147 institutional investors add shares of $AVAH stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J.H. WHITNEY EQUITY PARTNERS VII, LLC removed 9,180,664 shares (-25.3%) from their portfolio in Q2 2026, for an estimated $78,678,290
- SUMMIT PARTNERS L P removed 7,551,422 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $64,715,686
- OPHIR ASSET MANAGEMENT PTY LTD added 5,100,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $43,707,000
- BRAIDWELL LP added 3,065,106 shares (+inf%) to their portfolio in Q2 2026, for an estimated $26,267,958
- CITADEL ADVISORS LLC added 2,008,806 shares (+725.3%) to their portfolio in Q2 2026, for an estimated $17,215,467
- LITTLEJOHN & CO LLC removed 1,987,857 shares (-90.2%) from their portfolio in Q2 2026, for an estimated $17,035,934
- BLACKROCK, INC. added 1,909,141 shares (+34.7%) to their portfolio in Q2 2026, for an estimated $16,361,338
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AVAH Price Targets
Multiple analysts have issued price targets for $AVAH recently. We have seen 5 analysts offer price targets for $AVAH in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Andrew Mok from Barclays set a target price of $9.5 on 07/09/2026
- Ben Hendrix from RBC Capital set a target price of $10.0 on 06/03/2026
- David Macdonald from Truist Securities set a target price of $9.0 on 05/20/2026
- Scott Fidel from Stephens & Co. set a target price of $11.0 on 05/15/2026
- Sean Dodge from BMO Capital set a target price of $10.0 on 03/20/2026
Full Release
ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today the pricing of the previously announced secondary offering by certain selling stockholders (the “Selling Stockholders”), including affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers of the Company, of 15,000,000 shares of its common stock at a price of $11.75 per share (the “Offering”). Certain affiliates of J.H. Whitney Equity Partners VII, LLC have also granted the underwriter a 30-day option to purchase up to an additional 2,250,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders. The Offering is expected to settle on August 24, 2026, subject to customary closing conditions.
RBC Capital Markets is acting as the sole book-running manager for the Offering.
A shelf registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). Before you invest, you should read the prospectus in that registration statement, including the documents incorporated by reference therein, the accompanying prospectus supplement and other documents the Company has filed or will file with the SEC for more complete information about the Company and this Offering. You may get these documents, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281 by telephone at (877) 822-4089 by email: [email protected].
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Aveanna Healthcare
Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 39 states providing a broad range of pediatric and adult healthcare services, primarily focused on care in the home, including nursing, hospice, rehabilitation, occupational nursing in schools, therapy, and day treatment center services for medically complex and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.
Forward-Looking Statements
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2025 fiscal year filed with the SEC on March 19, 2026, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.